Clinical trials of SaliraVira® were performed under the supervision of the Infectious Diseases and Tropical Medicine Group of Tehran University Medical Sciences (TUMS), in Infection (Covid-19) Ward of IKHC.
170 outpatients randomly selected by the physicians of the ward including 87 in case group, 56 in control group, and 27 patients did not complete the trials. During clinical trials, Covid-19 outpatients were divided into two groups: “treatment or case” and “control”. Both groups were prescribed routine hospital medications. In parallel, the “treatment” group was also given SaliraVira®. Covid-19 patients were either diagnosed by PCR tests with “threshold cycle” (Ct) or approved based on symptoms by the physicians in the hospital. Covid-19 patients were randomly assigned to the “treatment” or “control” groups. Patients in the “treatment” group were given SaliraVira® package daily.
Overall improvement in Covid-19 patients
List of hospital routine medicines: Remdesivir, Interferon beta 1-alpha, Sovodak, Dexamethasone, Azithromycin, Favipiravir, Famotidine, Doxycycline, Naproxen, Vitamin C